首页> 外文OA文献 >Duplex/colour Doppler sonography: measurement of changes in hepatic arterial haemodynamics following intra-arterial angiotensin II infusion.
【2h】

Duplex/colour Doppler sonography: measurement of changes in hepatic arterial haemodynamics following intra-arterial angiotensin II infusion.

机译:双工/彩色多普勒超声检查:测量动脉内血管紧张素II输注后肝动脉血流动力学的变化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Angiotensin II (AT-II) has been used to target regionally-administered cytotoxic microspheres in patients with intrahepatic tumours. The optimisation of vasoconstrictor targeting requires a knowledge of the blood flow changes induced by agents such as AT-II. We therefore assessed duplex/colour Doppler sonography (DCDS) as a means of evaluating the effects of AT-II infusion on hepatic arterial blood flow (HABF) and arterial resistance in patients with intrahepatic tumours. HABF was measured continuously in nine patients using DCDS before, during and after an infusion of AT-II (15 micrograms in 3 ml of saline over 90 s) via a hepatic artery catheter. In seven patients with less than 30% hepatic replacement by tumour, the baseline level of HABF was 331 +/- 85 ml min-1 (mean +/- s.d.), and this was reduced by 75-80% within 30 s of the start of AT-II infusion. HABF recovered rapidly from the end of the infusion, and increased by up to 20% above the baseline for approximately 2 min. In two patients with greater than 50% hepatic replacement, HABF showed no reduction but rose continuously from the start of AT-II infusion, increasing by a factor of 2-2.5 after 3-4 min. Arterial resistance showed reciprocal changes in all cases. We conclude that DCDS is effective in assessing the temporal changes in hepatic arterial blood flow caused by AT-II. In order to optimise tumour targeting, the injection of microspheres loaded with cytotoxic drugs should be completed before the end of the AT-II infusion. The targeting advantage of AT-II in patients with a high percentage hepatic replacement by tumour should be re-assessed.
机译:血管紧张素II(AT-II)已被用于靶向肝内肿瘤患者的区域性细胞毒性微球。血管收缩剂靶向的优化需要了解由诸如AT-II之类的药物诱导的血流变化。因此,我们评估了双重/彩色多普勒超声检查(DCDS),作为评估AT-II输注对肝内肿瘤患者肝动脉血流量(HABF)和动脉阻力的影响的一种手段。在通过肝动脉导管输注AT-II(在90 s内于3 ml生理盐水中注入15微克)之前,之中和之后,使用DCDS对9名患者进行了连续的HABF测量。在7例因肿瘤肝脏置换不足的患者中,HABF的基线水平为331 +/- 85 ml min-1(平均+/- sd),并且在30 s内降低了75-80%。开始AT-II输液。 HABF从输注结束后迅速恢复,并在大约2分钟的时间内比基线高出多达20%。在两名肝替代率大于50%的患者中,HABF没有降低,但从开始AT-II输注开始持续上升,在3-4分钟后增加了2-2.5倍。在所有情况下,动脉阻力均显示相互变化。我们得出结论,DCDS可有效评估由AT-II引起的肝动脉血流的时间变化。为了优化肿瘤靶向,应在AT-II输注结束前完成装有细胞毒性药物的微球注射。应重新评估AT-II在高比例肝替代肿瘤患者中的靶向优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号